Verify any claim · lenz.io
Claim analyzed
Finance“The market size for peripheral arterial disease (PAD) in the United States is approximately $800 million in 2026.”
Submitted by Patient Owl 3539
The conclusion
Open in workbench →The claim is not supported by the available evidence. The most relevant U.S.-specific PAD market sources in the record place the market at roughly $1.6 billion to $2.7 billion or higher around 2023-2025, making an approximately $800 million U.S. figure for 2026 implausibly low. The only near-match is a global estimate, not a U.S. one.
Caveats
- Several listed sources are irrelevant or low-reliability, including sanitary-pad market pages and unverified LinkedIn posts.
- The argument appears to confuse market definitions and geography by using a global PAD estimate to justify a U.S.-only figure.
- No cited source directly reports a U.S. PAD market size near $800 million for 2026; the figure rests on speculation about a narrower sub-segment.
Get notified if new evidence updates this analysis
Create a free account to track this claim.
Sources
Sources used in the analysis
This peer-reviewed study focuses on epidemiology rather than market size, but it provides context for commercial forecasts. The authors project that "the number of PAD cases worldwide will increase by 220% by 2050, affecting an estimated 360 million people globally." This anticipated growth in PAD prevalence is frequently cited by market analysts as a key driver of expansion in PAD-related therapeutics and devices markets.
The article states: "The U.S. Peripheral Artery Disease Market was valued at USD 1.66 billion in 2025 and is expected to reach USD 2.96 billion by 2033" and describes this as part of the PAD market outlook for the United States. It further notes that the broader Artery Market size in 2025 was USD 4.80 billion globally and is projected to reach USD 8.65 billion by 2033, with a CAGR of 7.66% from 2026 to 2033.
The report states: "In 2023, the market size of Peripheral Artery Disease (PAD) was highest in the US among the 7MM, accounting for approximately USD 2,665 million which is further expected to increase by 2034." It also notes that "The market size was of nearly USD 4,055 million in the 7MM in 2023" and attributes future growth to an increase in diagnosed prevalent cases and the launch of emerging therapies, including ACP-01 in the US expected to be launched by 2026.
Straits Research reports: "The global peripheral artery disease market size was valued at USD 5.42 billion in 2025 and is projected to grow from USD 5.82 billion in 2026 to USD 10.31 billion by 2034 at a CAGR of 7.41% during the forecast period 2026-2034." In its FAQ section, it answers: "How large is the peripheral artery disease market in 2026?" with: "According to Straits Research, the peripheral artery disease market size is projected to grow at USD 5.82 billion in 2026."
SNS Insider states that "the U.S. Peripheral Artery Disease Market was valued at USD 1.66 billion in 2025 and is expected to reach USD 3.42 billion by 2035, growing at a CAGR of 7.51% from 2026 to 2033." In another section it lists a base year 2025E global PAD market size of USD 4.80 billion and projected USD 8.65 billion by 2033, with a CAGR of 7.66% from 2026 to 2033.
IMARC states: "The peripheral artery disease market size was valued at USD 5.1 Billion in 2025, expected to reach USD 7.9 Billion at a CAGR of 4.78% during 2026-2034." It further notes: "The global peripheral artery disease market size was valued at USD 4.89 Billion in 2024" and projects that "The market is projected to reach USD 7.74 Billion by 2033, exhibiting a CAGR of 4.98% from 2025-2033."
Data Bridge Market Research states: "The global peripheral arterial disease (PAD) market was valued at USD 873.01 million in 2024 and is expected to reach USD 1.74 billion by 2032." It adds that during the forecast period of 2025 to 2032, "the market is likely to grow at a CAGR of 9.00%, primarily driven by the increasing prevalence of PAD due to aging populations, rising risk factors such as diabetes and hypertension, and advancements in minimally invasive treatment options."
The report description states: "The global peripheral artery disease market size reached US$ 5.0 Billion in 2023." It further notes: "The market is projected to reach US$ 7.9 Billion by 2034, exhibiting a CAGR of 4.78% from 2026-2034. North America currently dominates the market, holding a leading share." These figures describe a multibillion‑dollar *global* PAD market and identify North America (which includes the U.S.) as the dominant region, with no indication that the U.S. market in 2026 would be as low as USD 800 million.
The report focuses on devices rather than disease, but provides context: "Global Peripheral Vascular Devices Market size is estimated to be valued at USD 14.42 Bn in 2026 and is expected to reach USD 22.70 Bn by 2033, exhibiting a compound annual growth rate (CAGR) of 6.7% from 2026 to 2033." It lists the "Market Size in 2026: USD 14.42 Bn" and describes a base year of 2025 for its forecasts.
MarketsandMarkets reports: "The global peripheral vascular devices market, valued at USD 9.55 billion in 2025, stood at USD 10.02 billion in 2026 and is projected to advance at a resilient CAGR of 5.7% from 2026 to 2031, culminating in a forecasted valuation of USD 13.22 billion by the end of the period." The table in the report lists "Market Size in 2025 (Value) | USD 9.55 Billion" and indicates incremental growth into 2026.
Grand View Research reports: "The global peripheral vascular devices market size was valued at USD 9.5 billion in 2025 and is projected to reach USD 16.1 billion by 2033, growing at a CAGR of 6.6% from 2026 to 2033." It specifies under report scope: "Market size value in 2026: USD 10.2 billion" and reiterates that "the global peripheral vascular devices market is expected to reach USD 10.2 billion in 2026." These figures apply to global peripheral vascular devices, a broader category than PAD, and are far above USD 800 million.
Precedence Research describes: "The global peripheral interventions market size is USD 11.30 billion in 2025, calculated at USD 12.32 billion in 2026 and is expected to reach around USD 54.59 billion by 2034." A summary table reiterates: "Market Size in 2025: USD 11.30 Billion" and "Market Size in 2026: USD 12.32 Billion." Again, this is a global figure for peripheral interventions (including PAD‑related procedures), significantly larger than USD 800 million.
This industry article discusses U.S. peripheral vascular devices rather than PAD therapeutics, but gives market context: it aims to "show where manufacturers can win in 2026" and refers to "procedure trends, competitor gaps, and emerging opportunities" in the U.S. peripheral vascular device market. While specific dollar figures are not in the short excerpt, the focus on 2026 U.S. peripheral vascular devices indicates an expectation of continued market growth driven by procedural volumes.
The repost of IMARC Group analysis states: "Looking forward, IMARC Group expects the market to reach USD 20.7 Billion by 2033, exhibiting a growth rate (CAGR) of 5.64% during 2025-2033." It refers to the global peripheral vascular devices market and describes a multi‑billion‑dollar trajectory by 2033, implying a 2026 market size well into the billions rather than less than a billion.
An industry analysis post on LinkedIn states: "United States Peripheral Arterial Disease Therapeutics Market Size, Strategic Outlook & Forecast 2026-2033. Market size (2024): USD 4.5 billion. Forecast (2033): 7.28 Billion USD. CAGR 2026-2033: 6.2%." It further notes that "the U.S. PAD therapeutics market is projected to reach approximately $2.5 billion by 2030, with a CAGR of 6-8%" and that the PAD therapeutics market "is valued in billions and shows consistent year-on-year growth."
Peripheral arterial disease is a medical condition, so a claim about a 'PAD market size' usually refers to the market for PAD treatments, devices, or diagnostics rather than the disease prevalence itself. The provided search results do not include a source that specifically reports a U.S. peripheral arterial disease market size of approximately USD 800 million in 2026.
This LinkedIn summary describes a report on "North America Peripheral Arterial Interventional Devices Market" noting a "projected 7.6% CAGR from 2026 to 2033." It refers to market size and trends in interventional devices across North America, providing regional context but not a specific 2026 U.S. PAD market value in the visible excerpt.
This result appears to concern a general **pads** market in Northern America, not peripheral arterial disease. The snippet mentions private-label and retail-brand pads representing an estimated 25–30% of unit sales in the United States and Canada.
This report covers the **feminine hygiene products** market, not peripheral arterial disease. It says the U.S. market is predicted to stand at USD 7.19 billion in 2026, while the North America market is expected to reach USD 11.34 billion in 2026.
This page is about **sanitary napkins**, not peripheral arterial disease. It states that the United States sanitary napkin market generated USD 5.98 billion in 2025 and is projected to reach USD 7.92 billion by 2034.
This source is about **reusable sanitary pads**, not peripheral arterial disease. It states that the market is estimated to be valued at USD 2,785.2 million in 2026 and expected to reach USD 5,497.0 million by 2033.
This page covers the **biodegradable sanitary pad** market, not peripheral arterial disease. It says the global market is forecast to be worth USD 1.38 billion in 2026 and reach USD 3.03 billion by 2035.
This source is about **sanitary pads**, not peripheral arterial disease. It estimates the sanitary pads industry size at USD 27.39 billion in 2026.
This page is about **back positioning pads**, not peripheral arterial disease. It states that the United States back positioning pad market was valued at USD 0.5 billion in 2024 and is projected to reach USD 1.0 billion by 2033, growing at a CAGR of 9.5% from 2026 to 2033.
This page covers **anti-overflow breast pads**, not peripheral arterial disease. It says the market is projected to expand at a CAGR of 7.5% during 2026-2033.
What do you think of the claim?
Your challenge will appear immediately.
Challenge submitted!
For developers
This same pipeline is available via API.
Verify your AI's output programmatically.
/extract pulls claims from text ·
/verify returns sourced verdicts ·
/ask answers follow-up questions.
Continue your research
Verify a related claim next.
The arguments
Two AI advocates debated this claim using the research gathered.
Argument for
Source 7 (Data Bridge Market Research) explicitly reports the global PAD market at USD 873.01 million in 2024, growing at a 9% CAGR, which projects to approximately USD 951 million globally by 2026 — making an $800 million U.S. estimate for 2026 plausible within that range, particularly if the U.S. represents the dominant share of a narrowly scoped therapeutics-only segment. Furthermore, Source 16 acknowledges that 'PAD market size' can refer specifically to treatments, devices, or diagnostics, meaning a more narrowly defined U.S. PAD therapeutics sub-segment in 2026 could reasonably align with the $800 million figure cited in the claim.
The Proponent's argument commits a scope-and-inference error by treating Data Bridge's much smaller “global PAD market” estimate (Source 7, Data Bridge Market Research) as compatible with an $800M U.S.-only figure, even though multiple PAD-specific sources in the brief already place the U.S. market alone at $1.66B in 2025 (Source 2, Yahoo Finance) and ~$2.665B in 2023 (Source 3, DelveInsight), making the Data Bridge number an outlier rather than a validating anchor. The Proponent then relies on Source 16 (LLM Background Knowledge) to hypothesize an undefined “narrow therapeutics-only sub-segment,” but neither Source 16 nor Source 7 provides any U.S. 2026 therapeutics segmentation or share data, so the $800M claim remains unsupported speculation rather than evidence-based estimation.
Argument against
The $800M U.S. PAD market-size figure for 2026 is contradicted by multiple PAD-specific market forecasts placing the U.S. market well above that level—e.g., Yahoo Finance reports USD 1.66B in 2025 for the U.S. alone (Source 2, Yahoo Finance) and DelveInsight estimates the U.S. PAD market at ~USD 2,665M in 2023 (Source 3, DelveInsight), making ~$800M in 2026 implausibly low. Even broader PAD market benchmarks are multi‑billion in 2026 (e.g., global PAD USD 5.82B in 2026 per Straits Research, Source 4), and the brief contains no credible source that actually reports a U.S. 2026 value near $800M (Source 16, LLM Background Knowledge), so the claim appears unsupported and inconsistent with the cited evidence.
The Opponent's reliance on Source 2 and Source 3 ignores the critical methodological distinction acknowledged in Source 16: 'PAD market size' can refer to narrowly scoped therapeutics-only segments versus broader device-inclusive markets, meaning the USD 1.66 billion and USD 2,665 million figures likely encompass a far wider scope than the $800 million therapeutics sub-segment claim. Furthermore, the Opponent dismisses Source 7 — which explicitly reports a global PAD market of USD 873.01 million in 2024 under a narrow scope — without accounting for the fact that if the U.S. represents the dominant share of that narrowly defined segment growing at a 9% CAGR, an $800 million U.S. figure for 2026 remains internally consistent with the available evidence rather than implausible.
Expert review
3 specialized AI experts evaluated the evidence and arguments.
Expert 1 — The Logic Examiner
The evidence that directly addresses the U.S. PAD market places it in the billions (e.g., USD 1.66B in 2025 in Source 2 and ~USD 2.665B in 2023 in Source 3), while the only sub‑billion figure (Source 7) is a global estimate and does not logically entail a U.S.-only 2026 value of ~$800M without additional segmentation/share premises that are not provided. Because the proponent's bridge from a global outlier estimate plus an unspecified “narrow sub-segment” (Source 16) to a concrete U.S. 2026 dollar figure is speculative and contradicted by multiple U.S.-specific forecasts, the claim is false on the presented record and implausible in light of the stronger contrary estimates.
Expert 2 — The Source Auditor
The most reliable sources on market size are the industry reports from Yahoo Finance (Source 2), DelveInsight (Source 3), and Straits Research (Source 4), which consistently place the U.S. PAD market well above $1.6 billion in 2025 and project continued growth, while Source 1 (NIH) provides no market data and Source 7's lower global figure is an outlier contradicted by the others. No authoritative independent source supports or reports a U.S. figure near $800 million for 2026, rendering the claim unsupported and refuted by the weight of credible evidence.
Expert 3 — The Precision Analyst
The claim states the U.S. PAD market size is approximately $800 million in 2026. Multiple PAD-specific sources directly contradict this: Source 2 (Yahoo Finance) places the U.S. PAD market at USD 1.66 billion in 2025 alone, Source 3 (DelveInsight) estimates the U.S. PAD market at ~USD 2,665 million in 2023, and Source 15 (LinkedIn) cites a U.S. PAD therapeutics market size of USD 4.5 billion in 2024. The only source that comes close to supporting the $800 million figure is Source 7 (Data Bridge), which reports a global PAD market of USD 873 million in 2024 — but this is a global figure, not a U.S.-only figure, and it is an outlier among market research firms. The proponent's argument that the U.S. could represent the dominant share of a narrowly scoped therapeutics segment worth ~$800 million is speculative and unsupported by any source that actually reports a U.S. 2026 value near $800 million. The claim's stated figure of ~$800 million for the U.S. PAD market in 2026 is materially inconsistent with the preponderance of evidence, which places the U.S. market in the range of $1.6–2.7 billion or higher, making the claim false as worded.